Yen Fu-Shun, Hsu Chih-Cheng, Wei James Cheng-Chung, Hou Ming-Chih, Hwu Chii-Min
Dr. Yen's Clinic, Taoyuan, Taiwan.
Institute of Population Health Sciences, National Health Research Institute, Miaoli, Taiwan.
Front Med (Lausanne). 2022 Feb 16;9:839456. doi: 10.3389/fmed.2022.839456. eCollection 2022.
The global prevalence of chronic liver disease and diabetes mellitus (DM) has gradually increased potentially due to changes in diet and lifestyle. The choice of antidiabetic medications for patients with coexisting DM and chronic liver disease is complicated. Severe liver injury may decrease the metabolism of antidiabetic medications, resulting in elevated drug concentrations and adverse effects. The choice of antidiabetic medications in patients with chronic liver disease has not been well studied. The long-term outcomes of antidiabetic medications in patients with chronic liver disease have gained attention recently. Herein, we reviewed relevant articles to extend our understanding on the selection and warning of antidiabetic medications for patients with chronic liver disease.
由于饮食和生活方式的改变，全球慢性肝病和糖尿病（DM）的患病率逐渐上升。对于同时患有糖尿病和慢性肝病的患者，抗糖尿病药物的选择很复杂。严重肝损伤可能会降低抗糖尿病药物的代谢，导致药物浓度升高和不良反应。慢性肝病患者抗糖尿病药物的选择尚未得到充分研究。抗糖尿病药物在慢性肝病患者中的长期疗效最近受到了关注。在此，我们回顾了相关文章，以加深我们对慢性肝病患者抗糖尿病药物选择和警示的理解。
